First Commercial Manufacturing Project Receives NMPA Approval-Newsroom

On May 11, 2024, the new commercial manufacturing site for Zimberelimab was officially approved by the National Medical Products Administration (NMPA) of China. This represents the first commercial project in which Intellective Bio successfully supported a client in obtaining marketing approval for a drug product, marking the official launch of Intellective Bio’s commercialization journey.

The Changshu site of Intellective Bio

The NMPA approval of the Zimberelimab manufacturing site is a significant milestone for our client and an especially proud achievement for Intellective Bio. It signifies the beginning of a new era of commercialization for the Company and demonstrates our capability to support clients throughout the entire product lifecycle, from development to commercial manufacturing.